High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer

被引:0
|
作者
Miyoshi, Y [1 ]
Ando, A [1 ]
Hasegawa, S [1 ]
Ishitobi, M [1 ]
Taguchi, T [1 ]
Tamaki, Y [1 ]
Noguchi, S [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Oncol, Suita, Osaka 5650871, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Prognostic significance of the intratumoral mRNA expression of three enzymes related to in situ estrogen biosynthesis, i.e., aromalase, sulfalase, and 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), was evaluated in patients with invasive breast cancer. Experimental Design: Aromalase, sulfatase, and 17beta-HSD1 mRNA levels in tumor tissues (n = 181) and normal breast tissues (n = 34) were examined by a quantitative, real-time PCR assay and compared with various clinicopathological factors as well as prognosis. Results: The sulfatase mRNA levels, but not the aromatase or 17beta-HSD1 mRNA levels, were significantly associated with lymph node metastases (P < 0.005), histological grade III (P < 0.001), and poor prognosis (P < 0.005). The association between the sulfatase mRNA and poor prognosis was found to be significant (P < 0.001) only in patients with estrogen receptor (ER)-positive tumors but not in ER negative tumors. In ER-positive tumors, the sulfatase mRNA levels was a significant prognostic factor independent of the lymph node status and histological grade by multivariate analysis. Conclusions: The sulfatase mRNA levels can serve as a significant, independent prognostic factor only in ER-positive tumors. It is speculated that the up-regulation of sulfatase mRNA levels leads to a high intratumoral estrogen concentration and, thus, an enhanced stimulation of tumor growth through ERs.
引用
收藏
页码:2288 / 2293
页数:6
相关论文
共 50 条
  • [1] High Ezrin Expression Is Linked To Poor Prognosis and Drug Resistance in Estrogen Receptor-Positive Breast Cancer
    Vanna, Sonal
    Hoskin, Victoria
    Ghaffari, Abdi
    Madarnas, Yolanda
    SenGupta, Sandip
    Elliott, Bruce
    LABORATORY INVESTIGATION, 2015, 95 : 71A - 71A
  • [2] High Ezrin Expression Is Linked To Poor Prognosis and Drug Resistance in Estrogen Receptor-Positive Breast Cancer
    Varma, Sonal
    Hoskin, Victoria
    Ghaffari, Abdi
    Madarnas, Yolanda
    SenGupta, Sandip
    Elliott, Bruce
    MODERN PATHOLOGY, 2015, 28 : 71A - 71A
  • [3] MZB1 expression indicates poor prognosis in estrogen receptor-positive breast cancer
    Watanabe, Manabu
    Shibata, Masahiro
    Inaishi, Takahiro
    Ichikawa, Takahiro
    Soeda, Ikumi
    Miyajima, Noriyuki
    Takano, Yuko
    Takeuchi, Dai
    Tsunoda, Nobuyuki
    Kanda, Mitsuro
    Kikumori, Toyone
    Kodera, Yasuhiro
    Nagino, Masato
    ONCOLOGY LETTERS, 2020, 20 (05)
  • [4] Higher CD73 Expression Is Associated with Poor Prognosis in Estrogen Receptor-Positive Breast Cancer
    Katsuta, Eriko
    Dasgupta, Subhamoy
    Yan, Li
    Takabe, Kazuaki
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : S34 - S34
  • [5] PITX2B mRNA expression is associated with poor prognosis in lymph nodenegative steroid hormone receptor-positive breast cancer
    Martens, John W.
    Sieuwerts, Anieta M.
    Meijer-Van Gelder, Marion E.
    Look, Maxime P.
    Bolt-De Vries, Joan
    Nimmrich, Inko
    Harbeck, Nadia
    Lesche, Ralf
    Hartmann, Oliver
    Portengen, Henk
    Schmitt, Manfred
    Maier, Sabine
    Klijn, Jan Gm
    Foekens, John A.
    CANCER RESEARCH, 2006, 66 (08)
  • [6] Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
    Bostner, Josefine
    Alayev, Anya
    Berman, Adi Y.
    Fornander, Tommy
    Nordenskjold, Bo
    Holz, Marina K.
    Stal, Olle
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 17 - 27
  • [7] Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
    Josefine Bostner
    Anya Alayev
    Adi Y. Berman
    Tommy Fornander
    Bo Nordenskjöld
    Marina K. Holz
    Olle Stål
    Breast Cancer Research and Treatment, 2018, 168 : 17 - 27
  • [8] MiR-187 is a marker of poor prognosis in estrogen receptor-positive breast cancer
    Mulrane, Laoighse
    Madden, Stephen
    Brennan, Donal J.
    Mcgee, Sharon F.
    Jirstrom, Karin
    van't Veer, Laura
    Bernards, Rene
    Higgins, Des
    Gallagher, William M.
    O'Connor, Darran P.
    CANCER RESEARCH, 2010, 70
  • [9] Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer
    Kenny, FS
    Hui, R
    Musgrove, EA
    Gee, JMW
    Blamey, RW
    Nicholson, RI
    Sutherland, RL
    Robertson, JFR
    CLINICAL CANCER RESEARCH, 1999, 5 (08) : 2069 - 2076
  • [10] High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients
    Egawa, C
    Miyoshi, Y
    Taguchi, T
    Tamaki, Y
    Noguchi, S
    INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (06) : 879 - 882